According to Cormedix's latest financial reports the company has $76.03 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $76.03 M | 29.32% |
2022-12-31 | $58.79 M | -10.19% |
2021-12-31 | $65.46 M | 41.24% |
2020-12-31 | $46.34 M | 63.58% |
2019-12-31 | $28.33 M | 60.77% |
2018-12-31 | $17.62 M | 47.06% |
2017-12-31 | $11.98 M | -40.57% |
2016-12-31 | $20.16 M | -43.01% |
2015-12-31 | $35.38 M | 715.43% |
2014-12-31 | $4.33 M | 82.8% |
2013-12-31 | $2.37 M | 184.14% |
2012-12-31 | $0.83 M | -57.92% |
2011-12-31 | $1.98 M | -76.03% |
2010-12-31 | $8.28 M | 450.35% |
2009-12-31 | $1.5 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Becton Dickinson BDX | $1.18 B | 1,454.63% | ๐บ๐ธ USA |
Utah Medical Products UTMD | $92.86 M | 22.15% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $0.11 B | 46.91% | ๐บ๐ธ USA |